Latest news with #JohnSheridan
BBC News
5 days ago
- Entertainment
- BBC News
Fondop's wall-mounted motivation to take Oldham up
Oldham Athletic's 116-year stay in the English Football League ended in ignominy in Latics picked up the unenviable record of becoming the first former Premier League club to drop out of the top four tiers of English years on from that chastening relegation, one man who has seen the club at its lowest ebb has set about leading the charge back to league Radio Manchester spoke to striker Mike Fondop about how he has motivated himself to lead Oldham to glory in Sunday's National League promotion final against Southend United at Wembley. The 31-year-old arrived at the club during Oldham's ill-fated 2022 season but injuries restricted him to just two the club losing its EFL status, Fondop stuck with the club and has scored 37 goals in 113 National League appearances what encouraged him to stay at Boundary Park?"The manager at the time, John Sheridan, called me after the end of the season and said 'I need you to come back. You owe me because I signed you and you only played two games. I want you to get this club back where it belongs'," Fondop said."So that has always been an objective because I came and I didn't have a chance to help them stay in League Two."The club doesn't belong in League Two, they belong higher than that but it is a step by step process."Between their relegation from League Two and the start of the following 2022-23 National League season, a takeover of the Latics by local businessman Frank Rothwell was ended Abdallah Lemsagam's tenure in control of the club and Fondop said that the difference between then and now is stark."The club is absolutely different now. The ownership now is more family orientated. The owners are approachable and want everyone to feel part of a family," he added."In the past it felt toxic. As a player I was focused on what I was signed to do but the environment at the time felt toxic. Now it is so different."If a club doesn't treat its players well you might think in the long run you can get away with it, you might for a period of time, but eventually it is going to affect results. Now the treatment is completely different." 'I wasn't even born last time Oldham won promotion' Oldham are not a club which have had much to celebrate in recent decades, having floated around the lower leagues of English football both before and after the turn of the millennium - having spent 21 years in the third tier prior to relegation to League Two in most recent promotion came in 1991 when they won the then-Division Two second tier recent record makes for grim reading. Their first season in the National League saw them finish 12th and was the first time they had finished in the top half of a division since said a team talk from boss Micky Mellon about how long it had been since the club had won promotion helped motivate him ahead of the trip to the capital."It has been 34 years since we experienced promotion. I'm 31 so last time they won promotion I wasn't even born," Fondop added."After the gaffer said that I went home and wrote down 34 years in bold on a piece of paper with my goals for the season and I put it on my kitchen wall. It's always in my mind."It's in my head every day because I want to be part of history and I want the fans to get back into the feeling of what Oldham deserves. It means more than people might think. It's in my kitchen until today and I'm not going to remove it until it is done."As for how he plans to ease his nerves ahead of running out at Wembley, Fondop has an eclectic and varied music taste."On gamedays I listen to gospel and that is what calms me," he said."I love Andrea Bocelli, Time To Say Goodbye is one of my favourites."I love jazz music as well, I don't have one specific type of song, I love a bit of everything. Usually in my downtime I can listen to opera and jazz. I don't like listening to things that give me headaches."
Agriland
22-04-2025
- Business
- Agriland
Planning approved to extend facilities at Ballyhaise
Teagasc has been granted planning permission by Cavan County Council to expand its facilities at Ballyhaise Agricultural College, Co. Cavan, including the construction of an extension to suckler sheds. The Agriculture and Food Development Authority was seeking permission for a suckler shed extension, a livestock underpass with an effluent tank and a sheep shed with underground slatted tanks. Planning was also approved for a wash and boot area, medicine store, toilet, office and training room and all associated site works. As part of the application for the development, Teagasc submitted its fertiliser plan for Ballyhaise Agricultural College to the council's planning department. Planning for the extension was granted subject to 22 conditions. Cavan County Council has ordered that the design and construction of all approvals shall be in accordance with the Department of Agriculture, Food and the Marine (DAFM) specifications. The college herd, which is spring calving, is part of the Teagasc Moorepark Dairy Research programme. Facilities include a modern 12 unit herringbone milking parlour with automatic drafting, slatted houses, calving pens and isolation boxes. Planning permission Meanwhile, planning permission has also been granted by Mayo County Council to construct an anaerobic digestion (AD) plant near Ballinrobe, Co. Mayo. The proposed AD plant on a site of approximately 4.4ha will take in 90,000 tonnes of locally sourced manure/slurry, whole crop silage and other organic material to produce biomethane. The planning application was submitted by local pig farmer John Sheridan and Nephin Renewable Gas and the application states that 71 local farmers are willing to supply feedstock to the proposed plant. The development would involve the construction of three digesters which would be around 16m in height, two digestate storage structures, two pump houses and two liquid feed tanks.
Yahoo
15-04-2025
- Business
- Yahoo
Q4 Earnings Outperformers: Tandem Diabetes (NASDAQ:TNDM) And The Rest Of The Healthcare Technology Stocks
Let's dig into the relative performance of Tandem Diabetes (NASDAQ:TNDM) and its peers as we unravel the now-completed Q4 healthcare technology earnings season. Healthcare Technology The 9 healthcare technology stocks we track reported a slower Q4. As a group, revenues beat analysts' consensus estimates by 2.3% while next quarter's revenue guidance was in line. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 17.2% since the latest earnings results. With technology that automatically adjusts insulin delivery based on continuous glucose monitoring data, Tandem Diabetes Care (NASDAQ:TNDM) develops and manufactures automated insulin delivery systems that help people with diabetes manage their blood glucose levels. Tandem Diabetes reported revenues of $282.6 million, up 43.6% year on year. This print exceeded analysts' expectations by 0.6%. Despite the top-line beat, it was still a slower quarter for the company with a significant miss of analysts' sales volume estimates. '2024 was a pivotal year for Tandem, as we returned to strong sales growth both in and outside of the United States, while delivering industry-leading customer satisfaction,' said John Sheridan, president and chief executive officer. Unsurprisingly, the stock is down 49.5% since reporting and currently trades at $16.97. Read our full report on Tandem Diabetes here, it's free. Founded in 2005 to streamline the traditionally paper-heavy patient check-in process, Phreesia (NYSE:PHR) provides software solutions that automate patient intake, registration, and payment processes for healthcare organizations while improving patient engagement in their care. Phreesia reported revenues of $109.7 million, up 15.4% year on year, outperforming analysts' expectations by 0.7%. The business had a strong quarter with a solid beat of analysts' EPS estimates and full-year EBITDA guidance topping analysts' expectations. The market seems content with the results as the stock is up 1.3% since reporting. It currently trades at $24.19. Is now the time to buy Phreesia? Access our full analysis of the earnings results here, it's free. Founded in 2011 to transform how healthcare is delivered to patients with complex needs, Evolent Health (NYSE:EVH) provides specialty care management services and technology solutions that help health plans and providers deliver better care for patients with complex conditions. Evolent Health reported revenues of $646.5 million, up 16.3% year on year, falling short of analysts' expectations by 0.7%. It was a softer quarter as it posted a miss of analysts' EPS estimates and EBITDA guidance for next quarter missing analysts' expectations significantly. Evolent Health delivered the weakest performance against analyst estimates and weakest full-year guidance update in the group. As expected, the stock is down 7.2% since the results and currently trades at $9.96. Read our full analysis of Evolent Health's results here. Operating one of the largest healthcare group purchasing organizations in the United States with over 4,350 hospital members, Premier (NASDAQ:PINC) is a technology-driven healthcare improvement company that helps hospitals, health systems, and other providers reduce costs and improve clinical outcomes. Premier reported revenues of $240.3 million, down 14.2% year on year. This number was in line with analysts' expectations. However, it was a slower quarter as it logged a significant miss of analysts' EPS estimates and full-year revenue guidance missing analysts' expectations. Premier had the slowest revenue growth among its peers. The stock is down 15.2% since reporting and currently trades at $19.01. Read our full, actionable report on Premier here, it's free. Driven by the vision of an "Autonomous Pharmacy" with zero medication errors, Omnicell (NASDAQ:OMCL) provides medication management automation and adherence tools that help healthcare systems and pharmacies reduce errors and improve efficiency. Omnicell reported revenues of $306.9 million, up 18.6% year on year. This result beat analysts' expectations by 2.2%. Taking a step back, it was a slower quarter as it recorded revenue guidance for next quarter missing analysts' expectations. The stock is down 29% since reporting and currently trades at $31.52. Read our full, actionable report on Omnicell here, it's free. Thanks to the Fed's rate hikes in 2022 and 2023, inflation has been on a steady path downward, easing back toward that 2% sweet spot. Fortunately (miraculously to some), all this tightening didn't send the economy tumbling into a recession, so here we are, cautiously celebrating a soft landing. The cherry on top? Recent rate cuts (half a point in September 2024, a quarter in November) have propped up markets, especially after Trump's November win lit a fire under major indices and sent them to all-time highs. However, there's still plenty to ponder — tariffs, corporate tax cuts, and what 2025 might hold for the economy. Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Growth Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here. Sign in to access your portfolio
Yahoo
18-03-2025
- Health
- Yahoo
Tandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the United States
– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – SAN DIEGO, March 18, 2025--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced the United States commercial launch of Control-IQ+ technology, the latest generation of the company's advanced hybrid closed-loop algorithm. Control-IQ+, compatible with both the t:slim X2 insulin pump and Tandem Mobi System, is now available for people with type 1 diabetes ages 2 years and older and adults with type 2 diabetes. Pumps pre-loaded with the updated software are now shipping to new customers, and all eligible, in-warranty Tandem customers will have access to the new features via remote software update free of charge. "These new features allow for even greater levels of personalization and flexibility within our algorithm, while still receiving high marks for ease of use across a diverse population of users," said John Sheridan, president and chief executive officer. "We are proud to offer this life-changing technology to millions more people living with diabetes." New features of the Control-IQ+ algorithm include: Expanded weight (20-440 lbs.) and total daily insulin (5-200 units) parameters to accommodate a wider range of insulin requirements. Enhanced extended bolus up to 8 hours with Control-IQ+ turned on, for better management for meals with delayed glucose rise or prolonged eating. New Temp Basal Rate adjustments allowed when Control-IQ+ is active, to address short-term glucose needs, such as exercise, stress, or illness, while Control-IQ+ is turned on. Control-IQ+ builds on the existing features of Tandem's industry-leading Control-IQ algorithm, which in addition to adjusting insulin every 5 minutes based on predicted glucose values, also uses a unique AutoBolus™ feature that calculates and delivers a correction bolus to help with missed meal boluses. Control-IQ+ is also the only AID algorithm that allows users to program extended boluses of up to 8 hours while automation is active to better manage delayed glucose rises or prolonged eating. "The benefits of AID are proven - better sleep, fewer adverse events and better glucose control - any one of these outcomes can be life changing for children living with diabetes and their families," said Dr. Paul Wadwa, director of the pediatric clinic at the Barbara Davis Center for Diabetes and professor of pediatrics at the University of Colorado School of Medicine. "Control-IQ+ is easy to start, use, and personalize. It's exciting to see continued advancement in the field that allows this technology to impact even more lives." All eligible, in-warranty Tandem users can access the software update for their pump by logging into their Tandem Source account: For more information on getting started with Tandem AID visit: About Tandem Diabetes Care, Inc. Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company's pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit Follow @TandemDiabetes on Facebook, Instagram, LinkedIn, TikTok, and X. ©2025 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ+, Control-IQ, t:slim X2, and Tandem Mobi are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. All other third-party marks are the property of their respective owners. Forward Looking Statements This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements relate to, among other things, the anticipated timing for the commercial launch of the t:slim X2 pump and the Tandem Mobi system with Control-IQ+ technology and our ability to offer the Control-IQ+ software update for current Tandem pump users. These statements are subject to numerous risks and uncertainties, including our ability to commence commercial scale manufacturing of the Tandem pump with Control-IQ+ technology and the risk that we may encounter other challenges that may delay the commercial launch of Tandem pumps with Control-IQ+ technology, as well as other risks identified in our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and other documents that we file with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors. Important Safety Information RX ONLY. The t:slim X2 pump with interoperable technology (the pump) and Control-IQ+ technology (Control-IQ+) are intended for single patient use. The pump and Control-IQ+ are indicated for use with NovoLog or Humalog U-100 insulin. t:slim X2 insulin pump: The pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in persons 2 years of age and greater. Control-IQ+ technology: Control-IQ+ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ+ technology is intended for the management of Type 1 diabetes mellitus in persons 2 years of age and greater and of Type 2 diabetes mellitus in persons 18 years of age and greater. WARNING: Control-IQ+ should not be used in anyone under the age of 2 years old with Type 1 diabetes or under the age of 18 years old with Type 2 diabetes. It should also not be used in patients who require less than a total daily insulin dose of 5 units of insulin per day or who weigh less than 20 pounds (9 kilograms), as those are the required minimum values needed for Control-IQ+ to operate safely. Users of the pump and Control-IQ+ must: use the insulin pump, iCGM, and all other system components in accordance with their respective instructions for use. Failure to follow these instructions for use could result in an over delivery or under delivery of insulin. This can cause hypoglycemia (low BG) or hyperglycemia (high BG) events. Visit for additional important safety information. View source version on Contacts Media Contact: 858-366-6900Media@ Investor Contact: 858-366-6900IR@
